Kilmax® is indicated for the treatment of infections caused by sensitive bacteria.

1. Pharyngitis /Tonsillitis caused by Streptococcus pyogenes.
2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains), Moraxella catarrhalis (including beta-Iactamase producing strains), or Streptococcus pyogenes.
3. Acute Bacterial Maxillary Sinusltls caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase producing strains only).
4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains).
5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes.
6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae.
7. Uncomplicated Gonorrhoea, urethral and endocervical caused by penicillinase-producing and non-penicillinase producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhoea, rectal, in females, caused by non-penicillinase producing strains of Neisseria gonorrhoeae.
8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi.
    
   
   

Oral:

Parenteral:

General doses and recommendation
Adults: Many, infections respond to 750 mg three times daily by 1M or IV injection. For more severe infections lhe dose should .be increased to 1.5 g IV three times daily. The frequency of administration may be increased to 6 hourly if necessary, giving total daily doses of 3 to 6 g. Infants and Children: 30 -100 mg/kg/day given as 3 or 4 divided doses. A dose of 60 mg/kg/day is appropriate for most infections.
Neonates: 30 - 100 mg/kg/day given as 2 or 3 divided doses.

Other recommendation
Gonorrhoea: 1.5 g as a single dose (as 2 x 750 mg injections intramuscularly with different sites, e.g. each buttock).

Meningitis: Cefuroxime sodium for injection is suitable for sole therapy of bacterial meningitis due to sensitive strains. Adults: 3 g IV every eight hours. Infants and Children 150-250 mg/kg/day IV in 3 or 4 divided doses. Neonates - The dosage should be 100 mg/kg/day IV.

Surgical Prophylaxis: The usual dose is 1.5 g of Cefuroxime intravenously before the procedure; this may be supplemented by 750 mg intramuscularly every 8 hours for up to 24 to 48 hours depending upon the procedure. In bone and Joint infections, a 1.5 g dose every 8 hours is recommended.

Sequential therapy:
Pneumonia:1.5 g three times daily or twice daily (given intravenously or intramuscularly) for 48-72 hours, followed by 500 mg twice daily oral therapy for 7-10 days.

Acute exacerbations of chronic bronchitis:
750 mg three times daily or twice daily (given intravenously or intramuscularly) for 48-72 hours, followed by 500 mg twice daily oral therapy for 5-10 days. Duration of both parenteral and oral therapy is determined by the severity of the infection and the clinical status of the patient.

In Impaired renal function:
Cefuroxime Sodium for injeclion should be reduced in renal impairment. It is not necessary to reduce the standard dose (750 mg -1.5 g three times daily) until the creatinine clearance falls to 20· mL/min or below. In adults with marked impairment (creatinine clearance 10- 20 mL/min) 750 mg twice daily is recommended and with severe impairment (creatinine clearance < 10 mL/min) 750 mg once daily is adequate. For patients on haemodialysis a further 750 mg dose should be given IV or 1M at the end of each dialysis. In addition to parenteral use, Cefuroxime can be incorporated into the peritoneal dialysis fluid.

Kilmax®  250 IM/IV Injection:
Intramuscular Injection: Add 1 ml Water for Injection to the vial and shake vigorously. Intravenous Injection: Add 2 ml Water for Injection to the vial and shake vigorously, the solution slowly injected directly into a vein over a 3 to 5 minutes period.

Kilmax®  750 IM/lV Injection:
Intramuscular Injection: Add 3 ml Water for Injection to the vial and shake vigorously. Intravenous injection: Add 8 ml Water for Injection to the vial and shake vigorously. The solution slowly injected directly into a vein over a 3 to 5 minutes period.

Store in a coo (below 30°c) and dry place, keep away from light. Keep out of the reach of children. In case of injection, use freshly prepared solution within 2 hours when kept at room temperature. Reconstituted solution is stable for 6 hours at room temperature and 24 hours in a refrigerator at 2° -8°C

Kilmax® 125 Tablet Box containing 2 strips of 7 tablets each.Each film coated tablet contains amorphousCefuroxime Axetil US? equivalent to Celuroxime 125 mg.

Kilmax® 250 tablet Box containing 2 strips of 7 tablets each. Each film coated tablet contains amorphous Cefuroxime Axetil US? equivalent to Cefuroxime 250 mg.

Kilmax® 500 tablet Box containing 1 strip of 7 tablets each. Each film coated tablet contains amorphous Cefuroxime Axetil USP equivaJent to Celuroxime 500 mg.

Kilmax® Powder for Suspension:  Bottle containing Powder for the preparation of 70 ml Suspension. Each 5 ml suspension contains amorphous Cefuroxime Axetil US? Equivalent to Cefuroxime 125 mg.

Kilmax®  250 IM/IV Injection :  Box containing one vial 01 250 mg Cefuroxime as sterile Gefwoxime Sodium USP and one ampoule of 5 ml pyrogen free Water for Injection USP.
 
Kilmax®  750 1M/IV Injection:  Box containing one vial of 750 mg Cefuroxime as sterile Cefuroxime Sodium USP and one ampoule of 10 ml pyrogen free Water for Injection USP.